| DRUG | VMAT2 (Vesicular Monoamine Transporter 2) Inhibitors  
|      | Austedo (deutetrabenazine)  
|      | Ingrezza (valbenazine)  
|      | Xenazine (tetrabenazine) |
| POLICY # | 21108 |
| INDICATIONS | Austedo and Xenazine are used in the treatment of chorea associated with Huntington’s Chorea.  
|      | Ingrezza is used for the treatment of tardive dyskinesia. |
| CRITERIA | For Huntington’s Chorea:  
|          | ConnectiCare considers Austedo to be medically necessary in patients 18 years of age and older when all the following criteria are met:  
|          | 1. The diagnosis of chorea associated with Huntington’s Chorea has been clinically established by, or in consultation with, a neurologist  
|          | AND  
|          | 2. The patient has had an intolerance to, or treatment failure of, generic tetrabenazine  
|          | In addition to the above criteria, Xenazine will be approved when the following criteria are also met:  
|          | 3. The patient has had an intolerance to, or treatment failure of, Austedo |
|          | For Tardive Dyskinesia:  
|          | ConnectiCare considers Austedo and Ingrezza to be medically necessary in patients 18 years of age and older when all the following criteria are met:  
|          | 1. The diagnosis of moderate to severe tardive dyskinesia has been clinically established by, or in consultation with, a neurologist or a psychiatrist, as well as indicated by a score of 3 or 4 on item 8 (severity of abnormal movements overall) of the Abnormal Involuntary Movement Scale (AIMS)  
|          | AND  
|          | 2. The patient has had an intolerance to, or treatment failure of, clonazepam |
### Pharmacy Pre-Authorization Criteria

| Limitations | None of the above medications will be approved to be used concomitantly with another vesicular monoamine transporter 2 (VMAT2) inhibitor.  
If the above medical necessity criteria are met authorization will be up to 3 months on initial approval and up to 12 months for reauthorization requests.  
A quantity limit for **Xenazine** will be limited to 60 tablets per month, to allow for a 50mg dose for CYP2D6 poor metabolizers. |
| REFERENCES | 1. Facts & Comparisons online  
| P&T Review History | 5/17, 11/17, 1/18 |
| Revision Record | 11/17 |

3. The patient must have been prescribed a drug that has Tardive Dyskinesia as a documented adverse reaction  
AND  
4. There is documentation of the member’s current AIMS score from items 1-7 (results range from 0 to 28, with higher scores indicating more severe involuntary movements).